Neurocrine announces Urocortin 2 phase II study results in acute decompensated ... pharmabiz.com Neurocrine Biosciences Inc., a biopharmaceutical company focused on neurological and endocrine diseases and disorders, has reported efficacy and safety results from a phase II trial of Urocortin 2 in 53 patients with acute decompensated heart failure. |
